Cargando…

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review

Endocrine therapy has played an essential role in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer. With the continuous development of endocrine targeting drugs, especially the emergence of selective cyclin-dependent kinase (CDK4/6) inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Shan, Wei, Guanjing, Hao, Yanrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358287/
https://www.ncbi.nlm.nih.gov/pubmed/37483648
http://dx.doi.org/10.3389/pore.2023.1611115
_version_ 1785075631613018112
author Gao, Shan
Wei, Guanjing
Hao, Yanrong
author_facet Gao, Shan
Wei, Guanjing
Hao, Yanrong
author_sort Gao, Shan
collection PubMed
description Endocrine therapy has played an essential role in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer. With the continuous development of endocrine targeting drugs, especially the emergence of selective cyclin-dependent kinase (CDK4/6) inhibitors, the overall survival time in patients with HR+HER2− advanced breast cancer has been greatly improved. Their adverse reactions also need more attention in response to the climbing number of CDK4/6 inhibitors. The common side effects of CDK4/6 inhibitors were hematological toxicity, diarrhea, and liver function damage. Skin toxicity related to CDK4/6 inhibitors was rare. We describe herein our preliminary observation of one HR+HER2− advanced metastatic breast cancer patient diagnosed with vitiligo-like lesions after 10 months of taking Palbociclib. Hoping to share our experience to increase the clinician awareness of this unusual adverse and contribute to the information in the literature.
format Online
Article
Text
id pubmed-10358287
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103582872023-07-21 Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review Gao, Shan Wei, Guanjing Hao, Yanrong Pathol Oncol Res Pathology and Oncology Archive Endocrine therapy has played an essential role in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer. With the continuous development of endocrine targeting drugs, especially the emergence of selective cyclin-dependent kinase (CDK4/6) inhibitors, the overall survival time in patients with HR+HER2− advanced breast cancer has been greatly improved. Their adverse reactions also need more attention in response to the climbing number of CDK4/6 inhibitors. The common side effects of CDK4/6 inhibitors were hematological toxicity, diarrhea, and liver function damage. Skin toxicity related to CDK4/6 inhibitors was rare. We describe herein our preliminary observation of one HR+HER2− advanced metastatic breast cancer patient diagnosed with vitiligo-like lesions after 10 months of taking Palbociclib. Hoping to share our experience to increase the clinician awareness of this unusual adverse and contribute to the information in the literature. Frontiers Media S.A. 2023-07-06 /pmc/articles/PMC10358287/ /pubmed/37483648 http://dx.doi.org/10.3389/pore.2023.1611115 Text en Copyright © 2023 Gao, Wei and Hao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pathology and Oncology Archive
Gao, Shan
Wei, Guanjing
Hao, Yanrong
Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
title Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
title_full Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
title_fullStr Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
title_full_unstemmed Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
title_short Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
title_sort vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor palbociclib: a case report and literature review
topic Pathology and Oncology Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358287/
https://www.ncbi.nlm.nih.gov/pubmed/37483648
http://dx.doi.org/10.3389/pore.2023.1611115
work_keys_str_mv AT gaoshan vitiligolikelesionsinducedbycyclindependentkinase46inhibitorpalbociclibacasereportandliteraturereview
AT weiguanjing vitiligolikelesionsinducedbycyclindependentkinase46inhibitorpalbociclibacasereportandliteraturereview
AT haoyanrong vitiligolikelesionsinducedbycyclindependentkinase46inhibitorpalbociclibacasereportandliteraturereview